You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 146 No. 11, November 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of β-Blockade on Right Ventricular Performance in Patients With and Without Right Ventricular Dysfunction due to Coronary Artery Disease

Amolak Singh, MD; Martin A. Alpert, MD; John F. Sanfelippo, MD; Vaskar Mukerji, MD; Daniel Villarreal, MD; Richard A. Holmes, MD; E. V. Sunderrajan, MD; Rebecca J. Morgan, RN

Arch Intern Med. 1986;146(11):2135-2139.


Abstract

• To assess the effects of β-blockade on right ventricular performance in patients with and without right ventricular dysfunction due to coronary artery disease, we performed radionuclide ventriculography on eight patients with normal right ventricular ejection fraction (RVEF≥35%) and 14 patients with mild to moderate right ventricular dysfunction (RVEF<35%) at rest. All patients had chronic stable angina pectoris, and nine patients had prior myocardial infarction. Radionuclide ventriculography was performed on placebo and during clinical β-blockade (heart rate, 50 to 60 beats per minute and ≤20% increase in heart rate over baseline during stage I treadmill exercise, Bruce protocol) with the oral, cardioselective β-blocking agent, betaxolol. The resting RVEF (mean±1 SD) was 33%±7% on placebo and 34%±7% during clinical β-blockade. Mean exercise RVEF was 40%±8% on placebo and 39%±8% during clinical β-blockade. These differences were not statistically significant. Resting left ventricular ejection fraction ranged from 22% to 60% (mean, 42%± 8%). On placebo, one of eight patients with a resting RVEF≥35% had a normal exercise RVEF response (≥5% increment) whereas nine of 14 patients with resting RVEF <35% had normal exercise response. The discordant relationship between baseline RVEF and exercise response on placebo became less marked during clinical β-blockade. We conclude that β-blockade does not produce significant deterioration of right ventricular systolic function or right ventricular reserve either in patients with normal or in those with mild to moderately impaired resting right ventricular systolic function.

(Arch Intern Med 1986;146:2135-2139)



Author Affiliations

From the Departments of Medicine and Radiology, Divisions of Cardiology and Nuclear Medicine, University of Missouri Health Sciences Center and Harry S Truman Memorial Veterans Hospital, Columbia.


Footnotes

Accepted for publication Feb 18, 1986.

Reprint requests to University of Missouri Health Sciences Center, Room 2N-18, 1 Hospital Dr, Columbia, MO 65212 (Dr Singh).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.